Blackstone pours more than €500mn into southern European hotels Date Monday, November 25, 2024 - 10:00 PM Description World’s largest real estate investor wants to capitalise on post-pandemic travel boom
Blackstone sells 3,000 homes worth £405mn to UK’s biggest pension fund Date Monday, August 12, 2024 - 10:00 PM Description Deal for shared ownership homes is buyout group’s first sale from its growing UK residential portfolio
Blackstone sells stake in €4bn Spanish hotel chain to GIC Date Tuesday, October 31, 2023 - 5:55 AM Description Deal raises more capital for US buyout group’s expansion at a time when borrowing costs have soared
Blackstone set to acquire Australian data centre business AirTrunk Date Tuesday, September 03, 2024 - 12:13 AM Description World’s largest private equity group is betting on growth of artificial intelligence in Asia-Pacific region
Blackstone switches to ‘best and final’ offer for Hipgnosis Date Tuesday, June 25, 2024 - 10:31 AM Description US private equity group moves to stop hedge funds with stakes in music rights owner from pushing for higher price
Blackstone-owned events organiser Clarion plans acquisition spree Date Monday, December 16, 2024 - 10:00 PM Description Trade fair group looks to double revenue as private equity backer plans sale
Blackstone’s big IPO bet Date Thursday, October 17, 2024 - 10:33 PM Description Plus, inside the relentless pursuit of 7-Eleven and Anne Wojcicki scrambles to save 23andMe
Blackstone’s liability to University of California doubles on property fund losses Image Date Monday, February 26, 2024 - 4:00 AM Description Breit has failed to deliver return promised to university in exchange for shoring up real estate fund
Blackstone’s private asset funds are tricky fit for retail investors Date Tuesday, January 09, 2024 - 11:48 AM Description The overall returns upside is greater — but so is the requirement for patience
Blackstone’s real estate prophecy Date Thursday, October 03, 2024 - 10:00 PM Description Plus, Kamala Harris drums up support from Wall Street and Chinese biopharma companies consider asset sales as new US regulations loom